{
    "symbol": "EIGR",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-06 20:23:01",
    "content": " These clearly position Eiger as a highly differentiated biopharmaceutical company with a diverse pipeline with major catalysts in our development programs for peginterferon lambda, lonafarnib and Avexitide as well as on the commercial front with Zokinvy, we believe that 2022 is shaping up to be a transformational year for Eiger. We are actively preparing for top line data from the Phase III D-LIVR study of lonafarnib-based regimens by the end of this year, a significant upcoming milestone for Eiger and for patients with HDV. Thank you so much. Thank you so much. Thank you so much. Thank you so much. Thank you so much."
}